Discontinuation report LORAZEPAM INJECTION USP
| Report ID | 106265 |
| Drug Identification Number | 02438704 |
| Brand name | LORAZEPAM INJECTION USP |
| Common or Proper name | LORAZEPAM |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | LORAZEPAM |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAVENOUS |
| Packaging size | 1ml x 1 vial |
| ATC code | N05BA |
| ATC description | ANXIOLYTICS |
| Reason for discontinuation | Other (Please describe in comments) |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2020-02-14 |
| Remaining supply date | 2020-12-31 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | unforeseeable supply issue |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2020-03-12 | French | Compare |
| v5 | 2020-03-12 | English | Compare |
| v4 | 2020-02-15 | French | Compare |
| v3 | 2020-02-15 | English | Compare |
| v2 | 2020-02-14 | English | Compare |
| v1 | 2020-02-14 | English | Compare |
Showing 1 to 6 of 6